Cargando…

Evaluation of atezolizumab immunogenicity: Efficacy and safety (Part 2)

Antibody therapeutics can be associated with unwanted immune responses resulting in the development of anti‐drug antibodies (ADA). Optimal methods to evaluate the potential effects of ADA on clinical outcomes in oncology are not well established. In this study, we assessed efficacy and safety, based...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peters, Solange, Galle, Peter R., Bernaards, Coen A., Ballinger, Marcus, Bruno, René, Quarmby, Valerie, Ruppel, Jane, Vilimovskij, Alexandr, Wu, Benjamin, Sternheim, Nitzan, Reck, Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8742640/ https://www.ncbi.nlm.nih.gov/pubmed/34582105 http://dx.doi.org/10.1111/cts.13149

Ejemplares similares

Evaluation of atezolizumab immunogenicity: Clinical pharmacology (part 1)
por: Wu, Benjamin, et al.
Publicado: (2021)

Prediction of overall survival in patients across solid tumors following atezolizumab treatments: A tumor growth inhibition–overall survival modeling framework
por: Chan, Phyllis, et al.
Publicado: (2021)

Allelic variation in HLA‐DRB1 is associated with development of antidrug antibodies in cancer patients treated with atezolizumab that are neutralizing in vitro
por: Hammer, Christian, et al.
Publicado: (2022)

Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer
por: Shemesh, Colby S., et al.
Publicado: (2019)

Fast progression in non–small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel
por: Gandara, David, et al.
Publicado: (2021)

Pan‐cancer population pharmacokinetics and exposure‐safety and ‐efficacy analyses of atezolizumab in patients with high tumor mutational burden
por: Shemesh, Colby S., et al.
Publicado: (2020)

Changes in Manufacturing Processes of Biologic Therapies Can Alter the Immunogenicity Profile of the Product
por: Vanderlaan, Martin, et al.
Publicado: (2019)

C-reactive protein reduction post treatment is associated with improved survival in atezolizumab (anti-PD-L1) treated non-small cell lung cancer patients
por: Patil, Namrata S., et al.
Publicado: (2021)

notch3 is essential for oligodendrocyte development and vascular integrity in zebrafish
por: Zaucker, Andreas, et al.
Publicado: (2013)

Atezolizumab-Conjugated Poly(lactic acid)/Poly(vinyl alcohol) Nanoparticles as Pharmaceutical Part Candidates for Radiopharmaceuticals
por: Ekinci, Meliha, et al.
Publicado: (2022)

Hepatic Events and Viral Kinetics in Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab
por: Hsu, Chiun, et al.
Publicado: (2022)

Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review
por: Ahmed, Faiza, et al.
Publicado: (2021)

Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial
por: Zhou, Caicun, et al.
Publicado: (2023)

Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects
por: Peters, Solange, et al.
Publicado: (2022)

Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment
por: Fehlings, Michael, et al.
Publicado: (2019)

Two Cases of Atezolizumab-Induced Hypophysitis
por: Kanie, Keitaro, et al.
Publicado: (2017)

Atezolizumab Treatment for Progressive Multifocal Leukoencephalopathy
por: Lambert, Nicolas, et al.
Publicado: (2022)

Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting
por: Morrissey, Kari M., et al.
Publicado: (2019)

Safety and efficacy of atezolizumab with obinutuzumab and bendamustine in previously untreated follicular lymphoma
por: Younes, Anas, et al.
Publicado: (2022)

Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma
por: Vithayathil, Mathew, et al.
Publicado: (2022)

Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non–Small-Cell Lung Cancer
por: Reck, Martin, et al.
Publicado: (2020)

Preexisting Antibodies to an F(ab′)(2) Antibody Therapeutic and Novel Method for Immunogenicity Assessment
por: Ruppel, Jane, et al.
Publicado: (2016)

Collagenous colitis and atezolizumab therapy: an atypical case
por: Gallo, Antonella, et al.
Publicado: (2020)

Atezolizumab-Induced Aseptic Meningitis in Patients with NSCLC
por: Toyozawa, Ryo, et al.
Publicado: (2020)

Safety and efficacy of atezolizumab in the treatment of cancers: a systematic review and pooled-analysis
por: Tie, Yan, et al.
Publicado: (2019)

ALICE: a randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer
por: Kyte, J. A., et al.
Publicado: (2020)

Atezolizumab and bevacizumab as first line therapy in advanced hepatocellular carcinoma: Practical considerations in routine clinical practice
por: Jain, Ankit, et al.
Publicado: (2021)

Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma
por: Vithayathil, Mathew, et al.
Publicado: (2023)

External validation of a tumor growth inhibition-overall survival model in non-small-cell lung cancer based on atezolizumab studies using alectinib data
por: Kassir, Nastya, et al.
Publicado: (2023)

Therapeutic Efficacy and Safety of Lenvatinib after Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma
por: Yano, Shigeki, et al.
Publicado: (2023)

A Rare Case Presentation of Vitiligo Associated With Atezolizumab
por: Nwanwene, Kemnasom, et al.
Publicado: (2023)

Hepatocellular carcinoma with gastric adenocarcinoma treated with atezolizumab and bevacizumab
por: Suga, Takayoshi, et al.
Publicado: (2023)

Atezolizumab Induces Necroptosis and Contributes to Hepatotoxicity of Human Hepatocytes
por: Endo, Yukinori, et al.
Publicado: (2023)

IMbrave150: Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: An Exploratory Analysis of the Phase III Study
por: Kudo, Masatoshi, et al.
Publicado: (2022)

Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1)
por: Kowanetz, Marcin, et al.
Publicado: (2018)

Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis
por: Tada, Toshifumi, et al.
Publicado: (2022)

Safety and efficacy of atezolizumab with rituximab and CHOP in previously untreated diffuse large B-cell lymphoma
por: Younes, Anas, et al.
Publicado: (2022)

Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancer
por: Rudin, C.M., et al.
Publicado: (2023)

Safety and Efficacy of Atezolizumab and Bevacizumab Combination as a First Line Treatment of Advanced Hepatocellular Carcinoma
por: Zanuso, Valentina, et al.
Publicado: (2023)

Use of Atezolizumab for Bladder and Non–Small Cell Lung Cancers
por: Moore, Kayla Faith
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_56v5t950raipjo85rmnccf82en